LONDON (ShareCast) - (Sharecast News) - Medical device company AorTech International announced on Wednesday that the United States Patent and Trademark Office has said that its application 15/995,050 would issue as US patent 10,676,560, entitled 'biostable polyurethanes', on 9 June.
The AIM-traded firm said the invention related to a biostable polyurethane, or 'polyurea' comprising a soft segment of a polysiloxane of the general formula disclosed in the patent, and a hard segment of between 0% and 40%, which is a reaction product of a diisocyanate and a linear difunctional chain extender.

It also included the processes for their preparation, and their use in the manufacture of biomaterials, implantable medical devices and polymeric heart valves.

"We are delighted that at the same time as major steps are being made in the development of our 'ElastEon' enabled medical devices, our intellectual property portfolio relating to the ElastEon family of world class biostable polymers has been expanded further by the grant of this latest US patent," said chairman Bill Brown.

"We currently anticipate reaching the significant milestone of commencing animal testing on the ElastEon sealed graft in the coming weeks."

At 1454 BST, shares in AorTech International were up 6.43% at 111.75p.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE